EMPLOYMENT AGREEMENTEmployment Agreement • March 12th, 2015 • Dicerna Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
This EMPLOYMENT AGREEMENT (“Agreement”) is made this 7th day of March 2014 (the “Effective Date”) between Dicerna Pharmaceuticals, Inc. (“Company”) on the one hand and Pankaj Bhargava (the “Executive”) on the other hand, the Company and the Executive together being the “Parties”.
DEVELOPMENT AND SUPPLY AGREEMENT By and Among PROTIVA BIOTHERAPEUTICS INC. And TEKMIRA PHARMACEUTICALS CORPORATION ON THE ONE HAND, And DICERNA PHARMACEUTICALS, INC. ON THE OTHER HANDDevelopment and Supply Agreement • March 12th, 2015 • Dicerna Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS DEVELOPMENT AND SUPPLY AGREEMENT (this “Supply Agreement”) is entered into as of November 16, 2014 (the “Effective Date”), by and among Dicerna Pharmaceuticals, Inc., a Delaware corporation having its principal place of business at 480 Arsenal Street, Building 1, Suite 120, Watertown, MA 02472 USA (“Dicerna”), on the one hand, and Protiva Biotherapeutics Inc. a British Columbia corporation having its principal place of business at 100-8900 Glenlyon Way, Burnaby, B.C.V5J 5J8, Canada (“Protiva”), and (with respect to Section 12.1(c) only) Tekmira Pharmaceuticals Corporation, a British Columbia corporation having its principal place of business at 100-8900 Glenlyon Way, Burnaby, B.C.V5J 5J8, Canada (“Tekmira”) on the other hand.
LICENSE AGREEMENT by and between DICERNA PHARMACEUTICALS, INC., on the one hand, and PROTIVA BIOTHERAPEUTICS INC. and TEKMIRA PHARMACEUTICALS CORPORATION on the other hand Dated: November 16, 2014License Agreement • March 12th, 2015 • Dicerna Pharmaceuticals Inc • Pharmaceutical preparations • New York
This LICENSE AGREEMENT (this “Agreement”) is entered into as of November 16, 2014 (the “Effective Date”), by and between Dicerna Pharmaceuticals, Inc., a Delaware corporation with offices at 480 Arsenal Street, Building 1, Suite 120, Watertown, MA 02472 USA and its Affiliates (“Dicerna”), on the one hand, and Protiva Biotherapeutics Inc., a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Protiva”), and Tekmira Pharmaceuticals Corporation, a British Columbia corporation with a principal place of business at 100-8900 Glenlyon Parkway, Burnaby, B.C., Canada V5J 5J8 (“Tekmira”), on the other hand.
